Pancreatic Cancer Clinical Trials (2026): 666 Recruiting Interventional Studies
Last updated: April 2, 2026
Current Clinical Trial Landscape
Active research areas in 2026:
- KRAS-targeted therapies (61 trials): G12C inhibitors, G12D-specific agents (RMC-9805), pan-RAS (daraxonrasib/RMC-6236), KRAS vaccines
- Immunotherapy combinations (100 trials): IO + chemo, IO + anti-angiogenic, stromal targeting
- BRCA/PALB2-directed (26 trials): platinum-based regimens, PARP inhibitors
- Claudin 18.2-targeted (ADCs, CAR-T), tumor treating fields, intra-arterial chemotherapy
Standard of care: FOLFIRINOX or gemcitabine/nab-paclitaxel for advanced disease. Olaparib maintenance for germline BRCA-mutated after platinum response.
Recruiting Trials by Treatment Stage
First-Line Metastatic
FOLFIRINOX or gemcitabine/nab-paclitaxel remain standard. Trials add novel agents:
- IO + chemotherapy:
- NCT06953999 - Ivonescimab (PD-1/VEGF bispecific) + Chemo ± AK117 (CD47) in metastatic PDAC (Phase 3)
- NCT07235930 - Sequential AG + mFOLFOX + Serplulimab + Bevacizumab vs AG alone (Phase 3)
- NCT06361888 - Surufatinib + Camrelizumab + Nab-paclitaxel + Gemcitabine (Phase 2/3)
- Novel combinations:
- NCT06079346 - OT-101 (TGF-β2 antisense) + mFOLFIRINOX (Phase 3)
- NCT07076121 - MountainTAP-30: BMS-986504 + Nab-paclitaxel + Gemcitabine vs Placebo (Phase 3)
- NCT05254171 - Nab-paclitaxel + Gemcitabine ± SBP-101 (polyamine inhibitor) (Phase 3)
- NCT07079228 - QLS31905 + Chemo vs Placebo + Chemo (Phase 3)
- BRCA/PALB2-mutated:
- NCT06783140 - NABPLAGEM vs Nab-paclitaxel/Gemcitabine in BRCA1/2 or PALB2-mutated PDAC (Phase 3)
- NCT06095141 - Cisplatin for PDAC with homologous recombination deficiency (Phase 3)
Second-Line / Pretreated
- NCT07066098 - G-HOPE-002: IBI343 (Claudin 18.2 ADC) vs Placebo in CLDN18.2+ pretreated PDAC (Phase 3)
- NCT06897644 - Gemcitabine + Nab-paclitaxel switch maintenance vs continuation mFOLFIRINOX (Phase 3)
- NCT01954992 - Glufosfamide vs 5-FU in second-line metastatic PDAC (Phase 3)
- NCT06998940 - Chemo ± Panitumumab for unresectable/metastatic PDAC (Phase 3)
Resectable / Borderline Resectable / Locally Advanced
- Neoadjuvant:
- NCT06714604 - Standard vs prolonged neoadjuvant chemo before surgery for BR/LAPC (Phase 3)
- NCT05529940 - NeoFOL-R: Perioperative vs adjuvant FOLFIRINOX in resectable PDAC (Phase 3)
- NCT05268692 - Neoadjuvant chemo followed by GS and GnP (Phase 3)
- NCT07081360 - Neoadjuvant vs upfront surgery for resectable PDAC (Phase 3)
- Adjuvant:
- NCT07252232 - Daraxonrasib (RMC-6236, pan-RAS) in resected PDAC (Phase 3)
- NCT07044453 - Risk-adapted adjuvant chemo guided by tumor stage after neoadjuvant (Phase 3)
- NCT06427447 - ADJUPANC: Adjuvant chemoradiotherapy vs chemo for PDAC (Phase 3)
- NCT04927780 - Perioperative vs adjuvant mFOLFIRINOX for resectable PDAC (Phase 3)
- NCT04969731 - Immuncell-LC (autologous immune cells) + Gemcitabine adjuvant (Phase 3)
- Locally advanced:
- NCT03257033 - Intra-arterial Gemcitabine vs IV Gem/Nab-pac after RT for LAPC (Phase 3)
- NCT06958328 - Higher dose radiation for locally advanced PDAC (Phase 3)
- NCT06250972 - Radiotherapy for CA19-9-elevated advanced PDAC (Phase 3)
KRAS-Targeted Therapies (61 trials)
Over 90% of pancreatic cancers have KRAS mutations. Once considered undruggable, KRAS is now a therapeutic target:
- Pan-RAS (multi-selective):
- NCT07252232 - Daraxonrasib (RMC-6236) adjuvant in resected PDAC (Phase 3)
- NCT05379985 - RMC-6236 in advanced solid tumors with RAS mutations (Phase 1/2)
- KRAS G12D-specific:
- NCT06040541 - RMC-9805 in KRAS G12D-mutant solid tumors (Phase 1)
- NCT07240766 - HRS-4642 + Nimotuzumab + Chemo for borderline resectable PDAC with KRAS G12D (Phase 2)
- KRAS G12V TCR-T cell therapy:
- NCT06898385 - IX001 TCR-T for advanced PDAC with KRAS G12V mutation (Phase 1)
- KRAS vaccines:
- NCT07353645 - KRAS neoantigen nanovaccine adjuvant for CRC/PDAC (Phase 1/2)
- NCT06411691 - KRAS-targeted vaccine + Balstilimab + Botensilimab for PDAC (Phase 1)
Novel Approaches
- Claudin 18.2-targeted: IBI343 (ADC, Phase 3), dual-target CAR-T (mesothelin + CLDN18.2), NCT07066995
- Tumor treating fields: NCT05653453 - TTFields + Gemcitabine + Nab-paclitaxel (Phase 3)
- Oligometastatic: NCT06593431 - EXPAND: Extending outcomes for PDAC with nominal oligometastatic disease (Phase 3)
- ctDNA-guided: NCT05482516 - Novel therapies in ctDNA-positive GI cancers; NCT06332274 - Tislelizumab for MRD+ cancers
- Intra-arterial chemotherapy: Direct hepatic artery or tumor infusion to overcome poor drug delivery in PDAC
Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.
Frequently Asked Questions
How do I find pancreatic cancer clinical trials?
Paste your medical summary into ClinTrialFinder to get AI-matched pancreatic cancer trials in minutes. The tool considers your KRAS mutation type (G12C, G12D, G12V), BRCA/PALB2 status, disease stage (resectable, borderline, locally advanced, metastatic), and prior treatments.
What pancreatic cancer trials are currently recruiting?
There are 666 recruiting interventional trials for pancreatic cancer including KRAS-targeted therapies (61 trials), immunotherapy combinations (100), BRCA/PALB2-directed treatments (26), Claudin 18.2-targeted agents, and novel approaches like tumor treating fields, intra-arterial chemotherapy, and mRNA vaccines.
Find Pancreatic Cancer Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your KRAS mutation, BRCA status, and disease stage.
Find Matching Trials
